Fine Print of Budget Deal Doesn't Bode Well for SGR Overhaul
GSK Drug Combination Approved for Advanced Melanoma
Immunotherapy in Cancer Care: Understanding the Impact of Shifting Treatment Paradigms in the Managed Care Setting
Post Marketing Research No Longer an Afterthought With Targeted Therapies
Reversing Halt, FDA Reauthorizes Sale of Ponatinib
Promising Results Halt Phase III Studies of Idelalisib
Adjuvant Pre- or Post-Operative Chemotherapy Does Not Improve Survival in Rectal Cancer
Collaboration Between Academia and Pharma to Bring New Therapies to Market More Important Than Ever
As Genomics Reveals Diversity of Lymphomas, Questions Arise on Diagnosis, Treatment, and Ethical Issues
When Less Is More: Results Herald 'Paradigm Shift' in Treating Newly Diagnosed Multiple Myeloma Patients
In Cancer and Beyond, Washington State Making the Transition to Value- Based Care
Sorting Out What Makes Sense in Diagnosing, Treating Prostate Cancer
Is Medicare Ready for Oncology Clinical Pathways?
Defining, Measuring, and Paying for the Work of Oncology Patient Navigators
A Test to Prevent Repeat Prostate Biopsies? Perhaps, if the Bar of 'Clinical Utility' Can Be Met
